Alliancebernstein L.P. Trims Stock Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Alliancebernstein L.P. cut its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 4.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 145,213 shares of the biopharmaceutical company’s stock after selling 6,511 shares during the quarter. Alliancebernstein L.P.’s holdings in Dynavax Technologies were worth $1,854,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DVAX. O Shaughnessy Asset Management LLC acquired a new stake in shares of Dynavax Technologies during the fourth quarter valued at about $131,000. Norges Bank acquired a new position in Dynavax Technologies during the fourth quarter worth $7,762,000. WINTON GROUP Ltd boosted its position in shares of Dynavax Technologies by 339.0% during the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company’s stock worth $5,450,000 after buying an additional 329,579 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at $883,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Dynavax Technologies in the fourth quarter valued at $358,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 21st. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. Finally, The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research note on Thursday.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock opened at $10.30 on Friday. The business has a 50-day simple moving average of $13.02 and a 200-day simple moving average of $12.56. The company has a market cap of $1.28 billion, a PE ratio of 57.21 and a beta of 1.26. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $14.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The company had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, equities research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.